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Abstract To compile an inventory of European health-
care databases with potential to study long-term effects of
methylphenidate (MPH) in patients with attention deficit
hyperactivity disorder (ADHD). Potential databases were
identified through expert opinion, the website of the Euro-
pean Network of Centres for Pharmacoepidemiology and
Pharmacovigilance, and literature search. An online survey
was conducted among database providers/coordinators to
ascertain the databases’ appropriateness for inclusion into
the inventory. It included questions about database char-
acteristics, sample size, availability of information on drug
exposure, clinical data and accessibility. Forty-two dat-
abases from 11 countries were identified and their coordi-
nators invited to participate; responses were obtained for 22
(52.4 %) databases of which 15 record ADHD diagnoses.
Eleven had sufficient data on ADHD diagnosis, drug
exposure, and at least one type of outcome information
(symptoms/clinical events, weight, height, blood pressure,
heart rate) to assess MPH safety. These were Aarhus Uni-
versity Prescription Database, Danish National Birth Cohort
(Denmark); German Health Interview and Examination
Survey for Children and Adolescents; Health Search
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Database Thales, Italian ADHD Register, Lombardy
Region ADHD Database (Italy); Avon Longitudinal Study
of Parents and Children, General Practice Research Data-
base, The Health Improvement Network, QResearch (UK)
and IMS Disease Analyzer (UK, Germany, France). Of the
20 databases with no responses, information on seven from
publications and/or websites was obtained; Pedianet and the
Integrated Primary Care Information database were con-
sidered suitable. Many European healthcare databases can
be used for multinational long-term safety studies of MPH.
Methodological research is underway to investigate the
feasibility of their pooling and analysis.
Keywords Database(s)  Methylphenidate 
Attention deficit hyperactivity disorder (ADHD) 
Drug safety  Paediatric
Background
As a first-line pharmacological therapy for attention deficit
hyperactivity disorder (ADHD), methylphenidate (MPH) is
widely prescribed in children and adolescents and to a
lesser extent to adults. The efficacy of MPH in ADHD has
been robustly demonstrated in randomised controlled trials
with approximately 70 % of children, adolescents and
adults showing a therapeutic response [1]. Other effective
drugs for ADHD are the potent psychostimulant dex-
amfetamine and atomoxetine, a selective noradrenaline
reuptake inhibitor. Although the medications for ADHD
are generally well-tolerated, commonly reported adverse
effects include neurological effects (such as headache,
insomnia), gastroenterological effects (loss of appetite,
nausea and vomiting, abdominal pain), psychiatric effects
(mood, anxiety) and chronic effects such as growth
restriction and increases in blood pressure [2, 3]. In order to
control the acute and chronic adverse effects of medication,
often patients on long-term ([1 year) drug treatment have
a structured interruption of treatment (known as a drug
holiday). This allows monitoring to ensure medication is
still effective, and assessment of whether the balance
between adverse effects and therapeutic effects favours the
continuation of treatment [3].
In 2006, there were safety concerns reported about the
use of amfetamines and MPH as treatments for ADHD,
specifically with respect to cardiovascular safety of these
products [4]. In 2007, the European Commission requested
a referral to the Committee for Medicinal Products for
Human Use (CHMP) under Article 31 of Directive
2001/83/EC, as amended, for MPH because of safety
concerns [5]. The CHMP concluded that insufficient was
known about the long-term adverse effects of MPH on
growth, sexual development, the neurological system,
psychiatric states and the cardiovascular system, and fur-
ther assessment is needed. In January 2009, the European
Medicines Agency (EMA) concluded that the benefit–risk
ratio of methylphenidate in the authorised indication
remains favourable, but more data are needed on the long-
term effects in children, adolescents and young adults [6].
In response to the CHMP’s concerns, the ADDUCE
(Attention deficit hyperactivity disorder drugs use chronic
effects) research team was formed by a consortium of
experts in the fields of ADHD, drug safety, neuro-psy-
chopharmacology and cardiovascular research. The
ADDUCE project, funded under the European Union’s 7th
Framework Programme, will use pharmacoepidemiological
research methods to investigate the long-term adverse
effects of MPH on growth, the neurological system
(including cognition and motivation), psychiatric states and
the cardiovascular system in children, adolescents and
adults. The methodologies employed will be the acquisition
and analysis of existing patient databases, a 2-year pro-
spective cohort study of MPH-treated patients and two
control groups, and a cross-sectional study in late adoles-
cents and young adults. A methodological overview of the
ADDUCE project is provided by the website (http://
adhd-adduce.org).
Electronic health care databases, comprising patient
data, drug prescription data, patient outcomes and infor-
mation on confounding variables, potentially provide
valuable resources to examine associations between drug
use and long-term adverse effects. A survey published in
2008 showed that many European healthcare databases had
enormous potential for use in paediatric drug utilisation
and safety studies [7]. The use of electronic health records
was also recommended by the EMA when conducting post-
authorisation drug utilisation and safety studies [8].
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Previous studies have demonstrated that healthcare
databases can be used to investigate certain adverse effects
of MPH. Gau et al. used the National Health Insurance
database (Taiwan) to assess the association between MPH
use and psychiatric disorders in 2,109 children and ado-
lescents with new onset ADHD between 1999 and 2003
matching 1:4 with non-ADHD controls. In this study, MPH
use was associated with the occurrence of bipolar disor-
der (adjusted hazard ratio (HR), 4.1; 95 % CI 1.7, 9.7,
p \ 0.05) [9]. McCarthy et al. aimed to estimate the
mortality rates associated with stimulant and non-stimulant
treatment prescription using the UK General Practice
Research Database (GPRD). Compared with the general
population, there was a 162-fold increased risk of com-
pleted suicide in patients aged 11–14 years using psycho-
stimulants or atomoxetine (standardized mortality ratio:
161.91 [95 % CI 19.61, 584.88]) [10]. Recently, four large
US health-plan databases of insurance claims were com-
bined to assess the use of ADHD drugs and the risk of
serious cardiovascular events (sudden cardiac death,
myocardial infarction, stroke) in children and young adults
[11]. A total of 81 serious cardiovascular events were
confirmed from over 2.5 million person-years of follow-up
giving an incidence of 3.1 events per 100,000 person-years
in the study cohort. Among current users of ADHD drugs,
there was no increased risk of serious cardiovascular events
when compared with non-users (adjusted HR, 0.75; 95 %
CI 0.31, 1.85), and there was no evidence of increased risk
for methylphenidate (adjusted HR, 0.96; 95 % CI 0.31,
2.97). Another study of claims data (Medicaid) from 28 US
states found that the treatment of children aged 3–18 years
with MPH or mixed amfetamine salts was not significantly
associated with an increased short-term risk of severe
cardiac events [12]. However, both US studies were unable
to assess the long-term safety of stimulant treatment due to
their short follow-up of 2 years [11, 12].
On the basis of these examples, we judged that analysis
of existing health care databases might be useful to study
the association between MPH use and long-term adverse
events. Although this might not be possible for all adverse
events of interest (e.g. sleep abnormalities), such databases
may provide important health information relevant for the
systematic study of side effects. However, many studies
performed in Europe have been limited in their power and
scope by the use of a single data source. Cooper et al. [11]
demonstrated the value of using multiple existing databases
in the US to obtain large sample sizes to study the safety of
ADHD drugs; adopting a similar approach in Europe may
be valuable if the issues concerning the pooling of such
databases could be overcome. Our previous work has
shown this to be feasible [13–16]. Hence, the aim of this
study is to compile an inventory of existing European
databases which can be used to study the effects of long-
term MPH use in patients with ADHD.
Methods
There were a number of steps taken to achieve our aim.
First, a list of all known potentially relevant European
databases with individual patient information was collated.
A range of different methods were used to identify eligible
databases: from those listed on the website of the European
Network of Centres for Pharmacoepidemiology and Phar-
macovigilance (ENCePP), a systematic review of the pub-
lished literature (including conference proceedings [17])
and finally, by nominations from members of the ADDUCE
Consortium.
Second, a questionnaire comprising 33 questions to
collect detailed database information was designed (by SI,
TB, MLM, SM, AN and ICKW) and implemented using a
web-based data collection tool (SurveyMonkeyTM). A
request to complete the questionnaire survey was sent to
the providers/coordinators of the identified databases.
Information collected on each database comprised general
information on the database (name, country), a description
of the nature of the database (e.g. longitudinal/patient
record database, disease registry, cross-sectional, observa-
tional data survey), characteristics and sample size (such as
number of investigators, database starting date, and number
of patients), availability of data on the exposure to medi-
cation and on symptoms and clinical events and accessi-
bility. Examples of questions are ‘‘Is information available
on ADHD diagnosis?’’; ‘‘Which of the following data are
recorded in the database? Weight, height, blood pressure,
heart rate’’ and ‘‘What system is used to code diagnoses?’’
Third, databases were categorised with respect to their
potential suitability for investigating the long-term safety
of MPH based on the availability of individual patient
information. Our criteria were based on the basic data
elements that are required for pharmacoepidemiologic
research using healthcare databases [18]. To be useful for
the investigation of the long-term safety of MPH use for
ADHD, databases had to record information about the
following clinical aspects of individual patients: ADHD
diagnosis, MPH exposure (dose and duration), exposure to
other medications, potential adverse outcomes (such as
effects on height and weight, blood pressure, heart rate)
and other symptoms/clinical events. Furthermore, infor-
mation on the structure and standardisation of data, costs to
access the database, completeness of clinical and drug
information and previous applications in research or vali-
dation studies were considered. The ability to combine with
data from other sources was also assessed based on whether
Eur Child Adolesc Psychiatry (2013) 22:605–618 607
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the database used unique patient identifiers (to allow for
record linkage) and coding systems for diagnoses, clinical
events and medications prescribed.
Last, detailed information of all databases without sur-
vey responses were sought from publications and the
websites of their data providers/coordinators, where pos-
sible information collated were based on that requested in
the survey questions. The databases were then assessed for
their potential suitability using similar criteria to those used
above.
Results
Response to the survey
Forty-two databases from 11 European countries were
identified and their providers/coordinators were invited to
participate in the survey (Fig. 1). Responses were obtained
from 22 (52.4 %) database coordinators/providers in seven
European countries (Table 1). Seven of these 22 databases
did not contain information on ADHD diagnosis; therefore,
15 databases were included in the detailed assessment.
Table 2 provides detailed information of the participating
databases. Only one database had an incomplete response
to the survey (Generation R study), however, it was pos-
sible to obtain some of the missing details from the liter-
ature [19, 20]. There was information on over 4.5 million
children and adolescents in these 15 databases (of which
just over 23,000 from six databases are reported to have
ADHD), this is an overestimate due to the possibility that
patients and/or their clinicians can contribute information
to more than one database. For example, there is an overlap
between GPRD and The Health Improvement Network
(THIN), where 66 % of contributing practices in THIN
also contribute to GPRD between 2001 and 2008 [21].
Type of database
Most of the selected databases are longitudinal/patient
record databases (n = 11). Two are ADHD specific patient
cohorts (Lombardy Region ADHD Database and the Italian
ADHD Register). One is a prescription information data-
base (Aarhus University Prescription Database) and one is
a cross-sectional, observational data survey (German
Health Interview and Examination Survey for Children and
Adolescents; KiGGS). Three databases could be linked to
various other registries through unique patient identifiers
(Aarhus University Prescription Database, Swedish Nati-
onal Health Data Registers and the National Psychiatric
Fig. 1 Survey and database assessment schematic flowchart
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Table 1 Databases identified and invited to participate in the survey
Country Purpose
of database
Database Website Response Information
from websites
and literature
Denmark PM National Psychiatric Central Register www.psykiatriskforskning.dk/
research/central-research-register/
Yes No
Denmark PM/Admin Odense Pharmacoepidemiological
Database
www.sdu.dk Yes No
Denmark PM/Admin Aarhus University Prescription Database kea.au.dk/en/informaticsand
statistics/researchdatabases/
theprescriptiondatabases/
Yes No
Denmark RC The Danish National Birth Cohort
(DNBC)
www.dnbc.dk/ Yes No
Finland PM/Admin Prescription register www.kela.fi No Yes
Finland RC The Finnish Northern Finland Birth
Cohort (NFBC) 1986 study
kelo.oulu.fi/NFBC/ No Yes
Germany RC The German Health Interview and
Examination Survey for Children and
Adolescents (KiGGS)
www.rki.de Yes No
Germany PM The German Population Based
Long-Term Follow-up of ADHD
www.bips.uni-bremen.de No Yes
Italy PM Pedianet www.pedianet.it/ No Yes
Italy PM Sistema Informativo Sanitario Regionale
Database-FVG region
www.regione.fvg.it No No
Italy PM Health Search Database Thales—CSD
LPD (HSD)
www.healthsearch.it/ Yes No
Italy PM Tuscany Regional database www.arsanita.toscana.it No No
Italy PM Lombardy Regional ADHD database givitiweb.marionegri.it/Centres/
Public/ADHD/Default.aspx
Yes No
Italy PM ARNO Observatory osservatorioarno.cineca.org/
arnoeng.htm
No No
Italy PM The National ADHD Registry www.farmaco-iss.org/ Yes No
Netherlands PM Integrated Primary Care Information
Database (IPCI)
www.ipci.nl No Yes
Netherlands PM PHARMO-Record-Linkage-System www.pharmo.nl Yes No
Netherlands PM InterAction database www.iadb.nl Yes No
Netherlands RC The Dutch KOALA Birth Cohort Study www.koala-study.nl Yes No
Netherlands RC The Dutch TRAILS study No No
Netherlands RC The Dutch Generation R study www.generationr.nl/ Yes No
Norway PM The Norwegian Prescription Database www.norpd.no/ Yes No
Portugal RC Centro de Estudos e Avaliac¸a˜o em Sau´de
(Centre for Health Studies and
Evaluation) (CEFAR)
No No
Sweden PM Swedish Medical Birth Register www.socialstyrelsen.se Yes No
Sweden PM Swedish National Health Data Registers www.socialstyrelsen.se Yes No
Sweden RC The Swedish All Babies in Southeast
Sweden
www.abis-studien.se/ No No
Spain PM Base de datos para la Investigacion
Farmacoepidemiologica en Atencion
Primaria (BIFAP)
www.bifap.org/ No No
UK PM General Practice Research Database
(GPRD) (now part of Clinical Practice
Research Datalink)
www.cprd.com/ Yes No
UK PM The Health Improvement Network Data
(THIN)
csdmruk.cegedim.com/ Yes No
UK PMS Prescription Event Monitoring (PEM) www.dsru.org/pem Yes No
UK Admin Prescription Pricing Authority (PPA) www.nhsbsa.nhs.uk/
PrescriptionServices.aspx
No No
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Central Register). The purpose of data collection of the
majority of databases was for patient management and
disease surveillance (n = 10); the remaining five are
research cohorts: Danish National Birth Cohort (DNBC),
KiGGS, Generation R Study, Dutch Child, Parent and
health: Lifestyle and Genetic constitution (KOALA) Birth
Cohort Study and Avon Longitudinal Study of Parents and
Children (ALSPAC).
Drug exposure
Almost all databases contain information on prescribed
medicines; Generation R Study does not collect details on
prescriptions or drug exposure. One (Lombardy Region
ADHD Database) has information on MPH and atomoxe-
tine only. Most (n = 14) include information on medical
diagnosis and the indication for prescription drugs. Four
databases (National Psychiatric Central Register, Genera-
tion R study, Swedish National Health Data Registers,
and ALSPAC) contain limited information on dosage
and duration of treatment. The Anatomical Therapeutic
Chemical classification system (ATC) is commonly used to
classify medications; 10 of the 15 databases use this coding
scheme [22, 23]. Multilex is a UK drug terminology system
used to classify medications and is used in the GPRD and
THIN databases. Only one database (KOALA) currently
does not use a medication coding system.
Clinical outcomes
Full clinical data (symptoms and clinical events, weight
and height, blood pressure and heart rate) are available in
eight databases [KiGGS, Italian ADHD Register, Lomb-
ardy Region ADHD register, KOALA, ALSPAC, GPRD,
THIN, and IMS Disease Analyzer (IMS DA)]. The Inter-
national Classification of Diseases 10th Revision (ICD-10)
is used as the diagnoses/clinical event coding system in
six databases (Aarhus University Prescription Database,
DNBC, National Psychiatric Central Register, Swedish
National Health Data Registers, ALSPAC, and IMS DA)
[24]. Read Clinical Terms (a UK hierarchical classification
system) is used in four UK databases (GPRD, THIN,
QResearch, and IMS DA). One database, Health Search
Database Thales (HSD), uses ICD-9 to code diagnoses and
clinical events.
Other variables
The diagnostic process for ADHD and hyperkinetic dis-
order includes the recognition of specific behavioural and
attentional symptoms per criteria of either the DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders,
4th edition) [25] or ICD-10. However, these symptoms are
also found in disorders other than ADHD [26, 27].
Therefore, information on whether the ADHD diagnosis
Table 1 continued
Country Purpose
of database
Database Website Response Information
from websites
and literature
UK PM QResearch www.qresearch.org/ Yes No
UK PM Scottish Programme for Improving
Clinical Effectiveness in Primary Care
(SPICE) formerly known as GPASS
(General Practice Administration
System for Scotland)
www.abdn.ac.uk/iahs/uploads/
files/PCI.pdf
No No
UK PM Medicines Monitoring Unit (MEMO) www.dundee.ac.uk/memo/ No No
UK RC The Avon Longitudinal Study of Parents
and Children (ALSPAC)
www.bristol.ac.uk/alspac/ Yes No
UK RC The 1970 British Cohort Study www.cls.ioe.ac.uk/bcs70 No Yes
UK RC The Millennium Cohort Study www.cls.ioe.ac.uk/mcs No Yes
UK RC The 2004 British Child and Adolescent
Mental Health Survey
No No
UK RC The Scottish SEATON Study www.abdn.ac.uk/seatonstudy/ Yes No
European RC The ADHD Observational Research in
Europe
No No
European RC The International Muti-Center ADHD
Genetics (IMAGE) Project
No No
UK, France,
Germany
PM IMS Disease Analyzer (IMS DA) www.imshealth.com/ Yes No
PM Patient management and/or disease surveillance, RC Research cohort, Admin administrative database for reimbursement and/or renumeration of
prescriptions, PMS post-marketing surveillance
610 Eur Child Adolesc Psychiatry (2013) 22:605–618
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had been validated is important. For two databases (Italian
ADHD Register and Lombardy Region ADHD Database),
clinicians use DSM-IV criteria to confirm diagnoses. In
DNBC and KiGGS, ADHD diagnosis is supported by
the scores from Strengths and Difficulties Questionnaire
(SDQ) [28], which has a scale measuring ADHD symp-
toms. Questionnaires to general practitioners (GPs) can be
used to obtain further information on diagnosis in the
GPRD and THIN databases.
Nine databases include information on ethnicity. Three
databases (DNBC, National Psychiatric Central Register,
and ALSPAC) also collect genetic information.
Previous applications of databases in the field of research
in paediatrics and/or ADHD
The Italian ADHD Register has been previously used in
studies on medication safety in ADHD patients [29–31].
The GPRD and THIN databases have been used to study
the safety and use of ADHD drug treatment [10, 32, 33].
Data from KiGGS has been used in a number of paediatric
studies, including those investigating the prevalence of
mental health disorders, such as ADHD and drug treatment
[34, 35]. ALSPAC has been widely studied and has
numerous publications in paediatric research but none in
ADHD.
Data access
All databases apart from one can be accessed either by
paying a fee and/or via academic collaboration. Nine of
them (DNBC, National Psychiatric Central Register,
KiGGS, HSD, Lombardy Region ADHD Database, KOALA,
Swedish National Health Data Registers, ALSPAC, IMS
DA) can be accessed via academic collaboration. The means
to access the Aarhus University Prescription Database was not
reported in the survey, but the literature states project-specific
permission from the Danish Data Protection Agency is
required and any data-linkage studies (which would be nec-
essary to obtain outcome data) need approval from the Danish
National Board of Health [36].
Assessment of non-responding databases
We obtained information on seven additional databases
whose coordinators did not reply to the survey. These were
Prescription Register (Finland), The Finish Northern Fin-
land Birth Cohort (NFBC) 1986 study, The German Pop-
ulation Based Long-Term Follow-up of ADHD, Pedianet
(Italy), Integrated Primary Care Information Database
(IPCI; Netherlands), The 1970 British Cohort Study and
The Millennium Cohort Study (UK). These databases were
appraised using the same criteria as above with information
obtained from database websites and published literature
(Table 3).
Type of database
Three of these seven databases are longitudinal/patient
record databases (the German Population Based Long-
Term Follow-up of ADHD, Pedianet and IPCI). Three are
longitudinal birth cohorts (NFBC, the 1970 British Cohort
Study, and The Millennium Cohort Study). Only one data-
base is a prescription information database [Prescription
Register (Finland)].
Drug exposure
Only two of the databases include information on indica-
tion of prescription and/or medical diagnosis (Pedianet and
IPCI). Information on dosage and duration of prescription
is available in Pedianet and IPCI, and both use the WHO
ATC classification system [22].
Clinical outcomes
Information on weight and height is found in Pedianet,
IPCI, the 1970 British Cohort Study and the Millennium
Cohort Study. Two databases provide information on
medical diagnosis and symptoms/clinical events (Pedianet
and IPCI). Only IPCI classifies diagnoses/clinical events
using the International Classification of Primary Care
(ICPC) code [37].
Other variables, previous applications in research
and data access
Due to limited information on these databases, the
availability of data on confounding variables and data
accessibility cannot be assessed. There is one study using
Pedianet to investigate the safety of paediatric drugs
[38]. No studies of paediatric drug safety using the IPCI
database could be identified in the literature. However,
both databases have been previously used to study pae-
diatric drug use [13–16]. A study describing the inci-
dence and prevalence of ADHD and drug treatment
for ADHD using The German Population Based Long-
term Follow-Up of ADHD database has been conducted
[39].
Selection of data source inventory
According to our criteria for suitability, 11 of the 15
responding databases were considered to have potential
value for the long-term safety evaluation of MPH. These
are Aarhus University Prescription Database, DNBC,
Eur Child Adolesc Psychiatry (2013) 22:605–618 613
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KiGGS, HSD, Italian ADHD Register, Lombardy Region
ADHD Database, ALSPAC, GPRD, THIN, QResearch and
IMS DA. Of the non-responding databases, Pedianet and
IPCI were considered potentially suitable. Hence, 13 dat-
abases were included in our data source inventory.
Discussion
From our survey, we identified 13 sources of electronic
health care records in Europe which have potential value in
investigating the long-term effects of MPH treatment in
patients with ADHD. These databases were selected
because they record basic data elements required to con-
duct drug safety studies; these include validated ADHD
diagnosis (or at least the ability to confirm diagnosis), other
diagnoses and clinical events, exposure to MPH, and
exposure to any other medications and potential adverse
clinical outcomes. These data are rich resources, easily
accessible, sourced from real-life practice, with the
potential to provide large study populations for the long-
term safety evaluation of MPH. Many are longitudinal in
nature, which is essential for the long-term follow-up of
patients.
However, it is generally recognised that existing sources
of data (including those we have identified) may have
several limitations such as selection bias, lack of control or
comparison group, missing data (or limited detailed clini-
cal information) [18], small sample sizes and issues of
quality control in data collection. For example, the selec-
tion of an un-medicated group of ADHD patients from the
13 data cohorts may be challenging due to the small
numbers of patients that exist (and would also affect pro-
spective cohort studies). Some data may be unrecorded
because the purpose of the database did not require it, such
as details of pubertal maturation, specific psychiatric rating
scales, measurements of brain function and activity (EEG,
fMRI), or risk factors such as developmental history,
parental history of medical and psychiatric problems and
life events. Other data may not be routinely entered at
specific time intervals (e.g. height, weight, blood pressure,
heart rate). Missing data may restrict the ability of some
data sources to be used to study specific long-term effects
(such as developmental or psychiatric effects), or even
threaten the reliability and validity of results, especially if
confounding variables are unavailable. Misclassified diag-
noses or outcomes can also affect the validity of a study.
The issue of small sample sizes could be overcome if data
are pooled to form larger cohorts. These issues are not
pertinent to all of the selected data sources in our inven-
tory, but they all should be carefully considered (and
addressed) when selecting data sources for our drug safety
research.T
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After consideration of these general limitations, the
ADDUCE Consortium proposed that high quality data
should be collected in a large prospective cohort study of
patients with ADHD and their controls. This cohort study
would collect specific information at set time points on
efficacy measures of MPH, growth, coordination, psychi-
atric effects (using rating scales such as DAWBA—
Developmental and Well-being Assessment modules),
neurological effects (rating scales, measures of brain
function and activity), as well as patient demographics,
family and personal medical, psychiatric and medication
histories and physical examinations (including cardiac
examinations). Much of these data are not recorded in the
existing data sources of our inventory. However, there are
also limitations to primary data collection of a large pro-
spective cohort; it is time- and resource-consuming, and
recruitment of a sufficiently large sample size to allow the
study of rare effects of MPH may be difficult. Hence studies of
large existing databases (single or pooled) in our inventory
would complement those of the prospective cohort.
There are opportunities to exploit the databases that we
have identified in our inventory; in particular, the combi-
nation of healthcare databases can potentially generate
sample sizes and statistical power for large-scale drug
safety studies [7]. European colleagues have recently
pooled eight existing electronic healthcare databases cov-
ering four countries to generate an early signal detection
system by creating a database platform using a common
data framework (EU-ADR) [40]. The different clinical
terminologies of the databases (e.g. Read Clinical Terms,
ICD-9) can be mapped using a biomedical terminology
integration system, Unified Medical Language System.
This generated a study population of almost 20 million
individuals with just under 60 million person-years of data.
Five of these databases are included in our inventory
(Aarhus University Prescription Database, HSD, QRe-
search, Pedianet and IPCI) [40]. However, the amalgama-
tion of existing databases is complex and goes beyond
issues of data structures and sources. There are ethical
issues concerning the processing of anonymised healthcare
data and national diversity in healthcare provision and
practice [7, 40]. Also, some of the limitations described
above such as the issue of data quality still remain, which
affect the choice of analytical methods. Database providers
may wish to improve the quality and completeness of
recording by the end-user and increase the availability of
more specific detailed clinical information (such as the
results of diagnostic tests) [18] to enhance the research
value of their databases. Despite the complexity of such a
task, the EU-ADR project [40] and other studies [11]
demonstrate that combining diverse databases of hetero-
geneous populations is feasible for drug safety research,
with vast potential for further work.
Conclusion
There are 13 European databases of birth cohorts or elec-
tronic healthcare records included in the ADDUCE data
inventory, which have potential value individually or
pooled for the evaluation of the long-term safety of MPH
treatment in patients with ADHD. They are rich sources of
data from real-life settings and easily accessible. However,
there are limitations in utilising existing sources of data
including small sample sizes, missing data and poor data
quality. The pooling of existing data sources presents
opportunities for large-scale safety studies of MPH in the
future; its feasibility is currently under investigation but
data quality and analysis, ethical issues and national dif-
ferences in healthcare provision need to be considered.
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